Clinical scores from murine collagen-induced arthritis study 2. Animals were given initial injection of type II collagen on day -21 and disease was induced with a second injection on day 0. On day 3 (arrow), pumps were implanted and clinical signs measured twice a week from day 6 to day 31. By day 9, a statistically significant, dose-dependent decrease in the clinical score was observed with all doses of CP-690550 and these remained significant to day 28. On day 31, only the high and mid dose of CP-690550 contained a statistically significant decrease in clinical score. At no time point during the course of the study did the anti-tumor necrosis factor (TNF) antibody treatment result in a statistically significant decrease in clinical score.